Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.47 |
| ▸ | GGT1 | P19440 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282947 | 0.88 | HSD17B10 (0.50) | HSD17B10KDM4ECYP1A2CYP2C9LMNA | |
| SCHEMBL4731573 | 0.86 | HSD17B10 (0.63) | HSD17B10KDM4ECYP1A2CYP2C9LMNA | |
| SCHEMBL29574954 | 0.86 | KDM4E (0.49) | HSD17B10KDM4ECYP1A2CYP2C9LMNA | |
| SCHEMBL7397616 | 0.85 | HSD17B10 (0.53) | HSD17B10KDM4ECYP1A2CYP2C9LMNA | |
| SCHEMBL1973304 | 0.84 | HSD17B10 (0.47) | HSD17B10KDM4ECYP1A2CYP2C9LMNA | |
| SCHEMBL6556774 | 0.84 | ELANE (0.44) | HSD17B10KDM4ECYP1A2CYP2C9LMNA | |
| SCHEMBL11853507 | 0.83 | HSD17B10 (0.41) | HSD17B10KDM4ECYP1A2CYP2C9LMNA | |
| Hydrogen Peroxide SCHEMBL29048859 | 0.83 | TSHR (0.48) | HSD17B10LMNAALDH1A1TSHRTDP1 | |
| SCHEMBL934637 | 0.82 | MAPT (0.58) | HSD17B10HPGDALDH1A1TSHRESR1 | |
| SCHEMBL2711658 | 0.82 | ELANE (0.43) | HSD17B10KDM4ECYP1A2CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-04-28 | — | — | US | disclosed |
| US-7910568-B2 | Inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, gastrointestinal disorders; prevention/treatment of colon cancer; releases hydrogen sulfide | ANTIBE THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7879827-B2 | such as 5-amino-2-(2-Acetylamino-3-mercapto-propionyloxy)-benzoic acid, useful for the treatment of gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome, and for the prevention/treatment of colon cancer | ANTIBE THERAPEUTICS INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-20090233886-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2009-09-17 | — | — | US | disclosed |
| US-7498355-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2009-03-03 | — | — | US | disclosed |
| EP-1996650-A2 | FLAME RETARDANT POLYCARBONATE COMPOSITIONS HAVING GOOD TRANSPARENCY AND LOW HAZE, METHOD OF MANUFACTURE, AND ARTICLES PREPARED THEREFROM | Sabic Innovative Plastics IP B.V. (NL) | 2008-12-03 | — | — | EP | disclosed |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | ANTIBE THERAPEUTICS INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| EP-1814950-A2 | THERMOPLASTIC WEAR RESISTANT COMPOSITIONS, METHODS OF MANUFACTURE THEREOF AND ARTICLES CONTAINING THE SAME | General Electric Company (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2007013890-A2 | THERMOPLASTIC WEAR RESISTANT COMPOSITIONS, METHODS OF MANUFACTURE THEREOF AND ARTICLES CONTAINING THE SAME | GENERAL ELECTRIC COMPANY (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007008476-A2 | POLYCARBONATE COMPOSITIONS HAVING INFRARED ABSORBANCE, METHOD OF MANUFACTURE, AND ARTICLES PREPARED THEREFROM | GENERAL ELECTRIC COMPANY (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-1725110-A2 | BIOCIDAL COMPOSITIONS AND METHODS OF MAKING THEREOF | General Electric Company, (a New York Corporation) (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1725610-A1 | BIOCIDAL COMPOSITIONS AND METHODS OF MAKING THEREOF | GENERAL ELECTRIC COMPANY (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1689580-A1 | MULTIWALL SHEETS AND METHODS FOR MANUFACTURING THEREOF | General Electric Company (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005087008-A2 | BIOCIDAL COMPOSITIONS AND METHODS OF MAKING THEREOF | GENERAL ELECTRIC COMPANY (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087855-A1 | BIOCIDAL COMPOSITIONS AND METHODS OF MAKING THEREOF | GENERAL ELECTRIC COMPANY (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005075550-A1 | INFRA-RED RADIATION ABSORPTION ARTICLES AND METHOD OF MANUFACTURE THEREOF | GENERAL ELECTRIC COMPANY (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005053953-A1 | MULTIWALL SHEETS AND METHODS FOR MANUFACTURING THEREOF | GENERAL ELECTRIC COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | HSD17B10 512/4885KDM4E 739/4885CYP1A2 1062/4885 |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | CBS, SI, TST | HSD17B10 496/4885KDM4E 422/4885CYP1A2 768/4885 |
| US-20090233886-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | HSD17B10 512/4885KDM4E 739/4885CYP1A2 1062/4885 |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | HSD17B10 512/4885KDM4E 739/4885CYP1A2 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.